3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
805
Uterine Cervical Neoplasms
412
Fallopian Tube Neoplasms
289
Endometrial Neoplasms
287
Carcinoma, Ovarian Epithelial
252
Neoplasms
95
Recurrence
83
Breast Neoplasms
83
Peritoneal Neoplasms
66
Uterine Neoplasms
55
Colorectal Neoplasms
55
Uterine Cervical Dysplasia
50
Sarcoma
49
Vulvar Neoplasms
47
Carcinoma, Non-Small-Cell Lung
45
Neoplasm Metastasis
44
Stomach Neoplasms
42
Pancreatic Neoplasms
36
Melanoma
34
Testicular Neoplasms
32
Lung Neoplasms
32
Prostatic Neoplasms
29
Vaginal Neoplasms
28
Papillomavirus Infections
25
Carcinoma
25
Head and Neck Neoplasms
23
Esophageal Neoplasms
23
Carcinoma, Renal Cell
23
Small Cell Lung Carcinoma
22
Urinary Bladder Neoplasms
21
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gynecologic
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled